Floatz logo

rd13-02 cell infusion

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2B
Abt-263
AbbVie
Phase 1/2B
Fludarabine
M.D. Anderson Cancer Center
Phase 2B

View all 33 →

Same molecule, other indications

rd13-02 cell infusion is also rated in:

hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
hematologic disorderDormant
CC
Indicative ·
47 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →